During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD, chaired a livestreamed RCC session that included lively discussion from Mike Atkins, MD; David McDermott, MD; and Brian Rini, MD. Together, they weigh the results of the RENOTORCH study findings presented at ESMO and whether those data influenced their opinions on first-line IO treatment for metastatic disease. They also consider the results of CheckMate 214, KEYNOTE-426, CheckMate 9ER, and CLEAR. ...
The Uromigos Live & Unplugged: Kidney Cancer
Advertisement
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
Dr. Regina Barragán-Carrillo discusses new data in the IO-refractory RCC setting that were presented during the RCC panel.
Scott Haake, MD, PhD, discusses his favorite frontline ccRCC data that were presented at Uromigos Live.
Benjamin Garmezy, MD, discusses what the best treatment strategies may be for RCC and the potential of IO-only strategies.
Dr. Monty Pal discusses the current IO-refractory RCC space and approaches to patients in the 2nd- and 3rd-line settings.
Dr. Beckermann shares why there is a need to identify a biomarker for patients with RCC who will benefit from belzutifan.
Dr. Saliby shares what she has liked about the RCC panels and how she sees space for new biomarkers and mechanisms of action.
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more.
Dr. Michael Atkins discusses long-term results of IO/TKI combinations for metastatic RCC and how they may influence debate.
Dr. David McDermott from Beth Israel Deaconess Medical Center discusses his favorite Uromigos guests and episodes.
Advertisement
